150 related articles for article (PubMed ID: 34850082)
1. Rituximab administration during the second trimester of pregnancy for systemic lupus erythematosus: Case report and review of the literature on rheumatic disease.
Colquhoun M; Thanopoulou V; Quick V; Mouyis M
Mod Rheumatol Case Rep; 2022 Jun; 6(2):173-177. PubMed ID: 34850082
[TBL] [Abstract][Full Text] [Related]
2. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
[TBL] [Abstract][Full Text] [Related]
3. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
Reis J; Aguiar F; Brito I
Acta Reumatol Port; 2016; 41(1):45-55. PubMed ID: 27115107
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.
Tambralli A; Beukelman T; Cron RQ; Stoll ML
J Rheumatol; 2015 Mar; 42(3):541-6. PubMed ID: 25593242
[TBL] [Abstract][Full Text] [Related]
5. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort.
Sawhney S; Agarwal M
Lupus; 2021 Oct; 30(11):1829-1836. PubMed ID: 34315295
[No Abstract] [Full Text] [Related]
6. Effectiveness and Safety of Rituximab in Systemic Lupus Erythematosus: A Case Series Describing the Experience of 2 Centers.
Gómez VJ; Carrión-Barberá I; Salman Monte TC; Acosta A; Torrente-Segarra V; Monfort J
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 2):391-395. PubMed ID: 30522941
[TBL] [Abstract][Full Text] [Related]
7. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
Galarza C; Valencia D; Tobón GJ; Zurita L; Mantilla RD; Pineda-Tamayo R; Rojas-Villarraga A; Rueda JC; Anaya JM
Clin Rev Allergy Immunol; 2008 Feb; 34(1):124-8. PubMed ID: 18270866
[TBL] [Abstract][Full Text] [Related]
8. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
9. Current perspective on rituximab in rheumatic diseases.
Schioppo T; Ingegnoli F
Drug Des Devel Ther; 2017; 11():2891-2904. PubMed ID: 29042750
[TBL] [Abstract][Full Text] [Related]
10. [Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case].
Sabugo F; Llanos C; Soto L; Gutiérrez J; Cuchacovich M
Rev Med Chil; 2005 Jun; 133(6):681-4. PubMed ID: 16075133
[TBL] [Abstract][Full Text] [Related]
11. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
[TBL] [Abstract][Full Text] [Related]
12. B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases.
Sangle SR; Lutalo PM; Davies RJ; Khamashta MA; D'Cruz DP
J Autoimmun; 2013 Jun; 43():55-9. PubMed ID: 23608146
[TBL] [Abstract][Full Text] [Related]
13. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
Sfikakis PP; Boletis JN; Tsokos GC
Curr Opin Rheumatol; 2005 Sep; 17(5):550-7. PubMed ID: 16093832
[TBL] [Abstract][Full Text] [Related]
14. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports.
Lim SW; Gillis D; Smith W; Hissaria P; Greville H; Peh CA
Intern Med J; 2006 Apr; 36(4):260-2. PubMed ID: 16640745
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
16. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab.
Saigal K; Valencia IC; Cohen J; Kerdel FA
J Am Acad Dermatol; 2003 Nov; 49(5 Suppl):S283-5. PubMed ID: 14576655
[TBL] [Abstract][Full Text] [Related]
17. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
Reddy V; Klein C; Isenberg DA; Glennie MJ; Cambridge G; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2017 Jul; 56(7):1227-1237. PubMed ID: 28407142
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.
Perrotta S; Locatelli F; La Manna A; Cennamo L; De Stefano P; Nobili B
Br J Haematol; 2002 Feb; 116(2):465-7. PubMed ID: 11841453
[TBL] [Abstract][Full Text] [Related]
19. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
Marinov AD; Wang H; Bastacky SI; van Puijenbroek E; Schindler T; Speziale D; Perro M; Klein C; Nickerson KM; Shlomchik MJ
Arthritis Rheumatol; 2021 May; 73(5):826-836. PubMed ID: 33277983
[TBL] [Abstract][Full Text] [Related]
20. Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature.
Van den Bergh B; Selleslag D; Boelaert JR; Matthys EG; Schurgers M; Vandecasteele S; De Vriese A
Acta Clin Belg; 2005; 60(2):102-5. PubMed ID: 16082997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]